Logo

AMRX

Amneal Pharmaceuticals, Inc.

AMRX

Amneal Pharmaceuticals, Inc. • NASDAQ
$12.52 ▲ 0.00% (+0.00)
Market Cap $3.94 B
52w High $12.68
52w Low $6.68
Dividend Yield 0%
P/E 1252
Volume 1.03M
Outstanding Shares 314.36M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $784.513M ▲ $274.091M ▲ $2.369M ▼ 0.302% ▼ $0.007 ▼ $111.664M ▼
Q2-2025 $724.508M ▲ $174.881M ▲ $22.417M ▲ 3.094% ▲ $0.071 ▲ $176.925M ▲
Q1-2025 $695.42M ▼ $155.544M ▼ $12.195M ▲ 1.754% ▲ $0.039 ▲ $154.584M ▲
Q4-2024 $730.518M ▲ $187.08M ▲ $-31.081M ▼ -4.255% ▼ $-0.1 ▼ $112.473M ▼
Q3-2024 $702.468M $180.749M $-156K -0.022% $-0.001 $139.895M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $201.249M ▲ $3.6B ▲ $3.71B ▲ $-109.458M ▲
Q2-2025 $81.186M ▲ $3.423B ▲ $3.47B ▲ $-112.533M ▲
Q1-2025 $59.187M ▼ $3.365B ▼ $3.425B ▼ $-131.667M ▼
Q4-2024 $112.42M ▲ $3.501B ▲ $3.546B ▲ $-109.267M ▼
Q3-2024 $74.006M $3.461B $3.495B $-93.432M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $18.132M ▼ $118.45M ▲ $-22.464M ▲ $59.443M ▲ $154.79M ▲ $103.4M ▲
Q2-2025 $35.61M ▲ $83.819M ▲ $-26.547M ▼ $-41.687M ▼ $15.416M ▲ $57.317M ▲
Q1-2025 $24.618M ▲ $7.408M ▼ $-17.798M ▼ $-39.166M ▲ $-50.026M ▼ $-10.914M ▼
Q4-2024 $-20.742M ▼ $118.078M ▼ $-16.059M ▲ $-61.204M ▲ $40.075M ▲ $95.014M ▼
Q3-2024 $11.757M $141.774M $-20.712M $-92.346M $28.723M $121.062M

Revenue by Products

Product Q3-2024Q1-2025Q2-2025Q3-2025
Amneal Specialty Pharma Segment
Amneal Specialty Pharma Segment
 $120.00M ▲$110.00M ▼$130.00M ▲$130.00M ▲
Specialty Segment
Specialty Segment
 $0 ▲$110.00M ▲$0 ▼$0 ▲
Generics Segment
Generics Segment
 $430.00M ▲$0 ▼$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue has grown steadily over the past several years, and profitability at the operating level has improved from a loss to a consistent profit. Margins look healthier than they used to, reflecting better mix, scale, and cost control. However, the company still reports net losses overall, mainly due to interest, amortization, and other below-the-line items. In plain terms: the core business is moving in the right direction, but the bottom line is not yet consistently in the black.

Balance Sheet

Balance Sheet The balance sheet shows a business that is heavily financed with debt and has only a thin equity cushion, which recently dipped into negative territory. Total assets have been relatively stable, but cash on hand is quite limited compared with the size of the debt load. This structure adds financial risk and makes the company more sensitive to interest costs, refinancing conditions, and business setbacks.

Cash Flow

Cash Flow Despite accounting losses, the company has been able to generate solid cash flow from its operations in most years. After investing in its facilities and equipment, it typically ends up with positive free cash flow, aside from a weak year in the middle of the period. Capital spending is meaningful but not excessive, suggesting a balance between maintaining and expanding capacity while preserving cash. Overall, cash generation is a relative strength compared with reported net income.

Competitive Edge

Competitive Edge Amneal operates in a tough, price-sensitive generic drug market but focuses on more complex, harder-to-make products where competition is thinner and barriers to entry are higher. Its broad portfolio of generics and specialty drugs, strong manufacturing base, and reputation for reliable supply give it an edge with large buyers. At the same time, it still faces intense competition from larger global generic players, ongoing price pressure, and regulatory hurdles that can quickly erode the profitability of any one product.

Innovation and R&D

Innovation and R&D The company’s innovation efforts are centered on complex generics, specialty neurology and endocrine drugs, and a growing biosimilars platform. It has invested in advanced manufacturing technologies and vertically integrated capabilities, which can support differentiated products and better control over quality and cost. The pipeline in biosimilars, injectables, and CNS treatments offers meaningful long-term opportunity, but carries typical pharmaceutical risks around clinical results, approvals, timing, and pricing once products reach the market.

Summary

Amneal shows a business with improving core operations, steady revenue growth, and decent cash generation, but weighed down by a high debt load and persistent net losses. Its strategy leans into areas of generics and specialty pharma where it can use technical know-how and manufacturing complexity to defend margins. The future story hinges on successful execution in complex generics, specialty products, and biosimilars, while carefully managing financial leverage and the inherent volatility of the drug market.

NEWS

November 13, 2025 · 4:01 PM UTC

Amneal Receives U.S. FDA Approval for Iohexol Injection

Read more

October 30, 2025 · 6:00 AM UTC

Amneal Reports Third Quarter 2025 Financial Results

Read more

October 29, 2025 · 4:05 PM UTC

Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol

Read more

October 27, 2025 · 8:00 AM UTC

Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches

Read more

September 30, 2025 · 4:05 PM UTC

Amneal to Report Third Quarter 2025 Results on October 30, 2025

Read more